Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
The interest from Eli Lilly and Novo in amylin as a potential therapeutic target for obesity and diabetes is significant, given the success of GLP-1 receptor agonists in these areas. Amylin, a peptide hormone co-secreted with insulin from the pancreas, has been shown to have effects on glucose metabolism and appetite regulation, making it an attractive target for treating metabolic disorders. By exploring amylin as a therapeutic target, these companies are likely seeking to expand their offerings in the obesity and diabetes markets.
The development of amylin-based therapies could provide an alternative or complementary approach to existing treatments, such as GLP-1 receptor agonists. This could be particularly important as the demand for effective obesity treatments continues to grow, driven by the increasing prevalence of obesity worldwide. Additionally, amylin-based therapies may offer benefits in terms of efficacy, safety, or patient convenience compared to existing treatments, which could help to differentiate them in a crowded market.
Looking ahead, it will be important to watch the progress of these amylin-based therapies in clinical trials and their potential impact on the obesity and diabetes treatment landscapes. Key questions to consider include the efficacy and safety of these therapies, as well as their potential for use in combination with other treatments. The commercial success of these therapies will also depend on factors such as pricing, reimbursement, and market competition, which will likely evolve over time as more data becomes available.
Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.